急诊科快速顺序插管的药物优化治疗
本文综述急诊科快速顺序插管(RSI)各阶段用药,包括预治疗、诱导、肌松及插管后镇静镇痛。预治疗药物阿托品、利多卡因、芬太尼因证据有限已较少使用;诱导药以依托咪酯和氯胺酮最常用,回顾性证据提示休克或脓毒症患者中依托咪酯可能低血压更少;肌松药首选琥珀胆碱或罗库溴铵,二者首次插管成功率差异极小,选择基于患者因素、半衰期和不良反应。未来需前瞻性研究确定休克或脓毒症患者最佳诱导药及剂量、肥胖患者用药及给药顺序。
要点
- 依托咪酯和氯胺酮是急诊RSI最常用诱导药,因血流动力学更有利。
- 回顾性证据显示,休克或脓毒症患者中依托咪酯可能比氯胺酮产生更少低血压。
- 琥珀胆碱与高剂量罗库溴铵首次插管成功率差异极小,选择基于患者因素、半衰期和不良反应。
- 预治疗药物阿托品、利多卡因、芬太尼因证据有限,已较少用于临床实践。
- 给药顺序(先肌松或先诱导)及肥胖患者剂量存在争议,证据不足,未显著改变当前实践。
适用人群与场景
- 急诊科需气管插管并接受快速顺序插管的患者。
- 接受药物辅助预氧合或清醒插管的急诊患者。
处置流程与药物剂量
- 快速顺序插管包括预治疗、诱导、肌松及插管后镇静镇痛等用药步骤。
- 预治疗药物包括阿托品、利多卡因、芬太尼,但临床使用已减少。
- 诱导药物中依托咪酯和氯胺酮最常用,因其血流动力学更有利。
- 休克或脓毒症患者中,回顾性证据提示依托咪酯可能产生较少低血压。
- 神经肌肉阻滞剂首选琥珀胆碱或罗库溴铵,高剂量罗库溴铵与琥珀胆碱首次插管成功率差异极小。
- 选择琥珀胆碱或罗库溴铵基于患者特定因素、半衰期和不良反应。
- 药物辅助预氧合和清醒插管用药需不同考虑。
研究设计与关键结果
- 综述指出,预治疗药物(阿托品、利多卡因、芬太尼)因证据有限,已较少用于临床。
- 依托咪酯和氯胺酮是最常用诱导药,因血流动力学更有利。
- 回顾性证据提示,休克或脓毒症患者中依托咪酯可能比氯胺酮产生更少低血压。
- 琥珀胆碱与高剂量罗库溴铵首次插管成功率差异极小。
- 给药顺序(先肌松或先诱导)及肥胖患者剂量存在争议,但证据不足,未显著改变当前实践。
- 需进一步研究RSI期间清醒瘫痪,才能对用药做出明确广泛实践改变。
证据类型、等级与局限
- 综述。
- 局限:最优选择、剂量和给药复杂,多个领域需进一步研究;需前瞻性研究确定休克或脓毒症患者最佳诱导药及剂量;给药顺序和肥胖患者剂量争议证据不足;需进一步研究RSI期间清醒瘫痪。
对床旁实践的改变
- 作者认为,急诊RSI诱导可选用依托咪酯或氯胺酮,休克或脓毒症患者中依托咪酯可能低血压更少。
- 作者认为,肌松药可选琥珀胆碱或高剂量罗库溴铵,依据患者因素、半衰期和不良反应选择。
- 预治疗药物阿托品、利多卡因、芬太尼因证据有限,已较少使用。
- 给药顺序和肥胖患者剂量争议证据不足,未显著改变当前实践。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Rapid-sequence intubation (RSI) is the process of administering a sedative and neuromuscular blocking agent (NMBA) in rapid succession to facilitate endotracheal intubation. It is the most common and preferred method for intubation of patients presenting to the emergency department (ED). The selection and use of medications to facilitate RSI is critical for success. The purpose of this review is to describe pharmacotherapies used during the RSI process, discuss current clinical controversies in RSI medication selection, and review pharmacotherapy considerations for alternative intubation methods.
SUMMARY: There are several steps to the intubation process requiring medication considerations, including pretreatment, induction, paralysis, and post-intubation sedation and analgesia. Pretreatment medications include atropine, lidocaine, and fentanyl; but use of these agents in clinical practice has fallen out of favor as there is limited evidence for their use outside of select clinical scenarios. There are several options for induction agents, though etomidate and ketamine are the most used due to their more favorable hemodynamic profiles. Currently there is retrospective evidence that etomidate may produce less hypotension than ketamine in patients presenting with shock or sepsis. Succinylcholine and rocuronium are the preferred neuromuscular blocking agents, and the literature suggests minimal differences between succinylcholine and high dose rocuronium in first-pass success rates. Selection between the two is based on patient specific factors, half-life and adverse effect profiles. Finally, medication-assisted preoxygenation and awake intubation are less common methods for intubation in the ED but require different considerations for medication use.
AREAS FOR FUTURE RESEARCH: The optimal selection, dosing, and administration of RSI medications is complicated, and further research is needed in several areas. Additional prospective studies are needed to determine optimal induction agent selection and dosing in patients presenting with shock or sepsis. Controversy exists over optimal medication administration order (paralytic first vs induction first) and medication dosing in obese patients, but there is insufficient evidence to significantly alter current practices regarding medication dosing and administration. Further research examining awareness with paralysis during RSI is needed before definitive and widespread practice changes to medication use during RSI can be made.
参考来源
- Engstrom K, Brown CS, Mattson AE, et al. Pharmacotherapy optimization for rapid sequence intubation in the emergency department. Am J Emerg Med. 2023. PMID: 37196592. doi:10.1016/j.ajem.2023.05.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。